Axon Sports

SoniVie Raises $60m in Round C Financing, and Appoints New Board Members

Retrieved on: 
Monday, January 9, 2023

TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.

Key Points: 
  • In conjunction with the financing, the Company appointed two renowned medtech experts to its Board of Directors, Raymond W. Cohen and Zeev Zehavi, as independent directors.
  • The proceeds from SoniVie financing are envisioned to be used to reach clinical and regulatory milestones and to support TIVUS™ renal artery denervation program.
  • Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
  • We are thrilled to support this talented management together with our syndicate partners and our new board members".

SoniVie Raises $60m in Round C Financing, and Appoints New Board Members

Retrieved on: 
Monday, January 9, 2023

TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.

Key Points: 
  • In conjunction with the financing, the Company appointed two renowned medtech experts to its Board of Directors, Raymond W. Cohen and Zeev Zehavi, as independent directors.
  • The proceeds from SoniVie financing are envisioned to be used to reach clinical and regulatory milestones and to support TIVUS™ renal artery denervation program.
  • Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
  • We are thrilled to support this talented management together with our syndicate partners and our new board members".

EQS-News: Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension

Retrieved on: 
Sunday, January 22, 2023

TEL AVIV, ISRAEL, AND PARIS, FRANCE, JANUARY 10, 2023 -- SoniVie Ltd. ("SoniVie" or the "Company"), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds. Current SoniVie shareholder TechWald also participated.

Key Points: 
  • Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension
    The issuer is solely responsible for the content of this announcement.
  • The financing was led by Andera Partners, with participation from Supernova Invest and Omega Funds.
  • Raphaël Wisniewski of Andera Partners commented, "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
  • We are thrilled to support this talented management together with our syndicate partners and our new board members".

EQS-News: Andera Partners raises its largest life sciences fund at €456M, demonstrating the attractiveness of its activity and of the sector

Retrieved on: 
Monday, October 10, 2022

Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector

Key Points: 
  • Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector
    The issuer is solely responsible for the content of this announcement.
  • Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector
    PARIS, 10 OCTOBER 2022 Andera Life Sciences, the business line specialising in innovative therapeutics and medical technologies of the asset management company Andera Partners, has announced the finalisation of its fundraising for its BioDiscovery 6 fund at 456 million euros.
  • The sixth generation of BioDiscovery funds is consolidating Andera Partners position as one of the leading players in life sciences venture capital in Europe.
  • Its teams manage over 3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).

Nyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of Directors

Retrieved on: 
Friday, May 6, 2022

Mr. Deyo has served on Nyxoahs board since 2016 and Mr.Janssen since 2018.

Key Points: 
  • Mr. Deyo has served on Nyxoahs board since 2016 and Mr.Janssen since 2018.
  • Mr. Cohen has served as Chief Executive Officer and board member of Axonics, Inc. (Nasdaq: AXNX) since co-founding the company in 2013.
  • From 2010 to 2012, he served as CEO of Vessix Vascular, a venture capital-backed renal denervation company that was acquired by Boston Scientific in November 2012.
  • Currently, Mr. Cohen serves as the Chairman of the board of directors at BioVentrix Inc., a privately-held transcatheter ventricular restoration company.

DGAP-News: Andera Partners to sell its Life Sciences' portfolio company ReViral to Pfizer

Retrieved on: 
Tuesday, April 12, 2022

Paris, April 7th, 2022 - Andera Partners, a leading European private equity player, through its practice Andera Life Sciences, focused on investments in companies developing breakthrough therapeutics and medical technologies, announced today that Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences' portfolio company ReViral Ltd.

Key Points: 
  • Paris, April 7th, 2022 - Andera Partners, a leading European private equity player, through its practice Andera Life Sciences, focused on investments in companies developing breakthrough therapeutics and medical technologies, announced today that Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences' portfolio company ReViral Ltd.
  • Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally.
  • Its teams manage over 3.2 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).
  • Andera's 15-person life sciences team brings together extensive experience in the life sciences industry, private equity and venture capital.

Andera Partners to sell its Life Sciences’ portfolio company ReViral to Pfizer

Retrieved on: 
Thursday, April 7, 2022

Andera Partners, a leading European private equity player, through its practice Andera Life Sciences, focused on investments in companies developing breakthrough therapeutics and medical technologies, announced today that Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences portfolio company ReViral Ltd.

Key Points: 
  • Andera Partners, a leading European private equity player, through its practice Andera Life Sciences, focused on investments in companies developing breakthrough therapeutics and medical technologies, announced today that Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences portfolio company ReViral Ltd.
  • Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally.
  • Its teams manage over 3.2 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).
  • Andera's 15-person life sciences team brings together extensive experience in the life sciences industry, private equity and venture capital.